PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

The surge of online weight-loss drug providers is unexpectedly fueling demand for a much older, once-stigmatized treatment: ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

In recent years, the landscape of diabetes and weight management has been significantly altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, initially developed ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support Patch Collection—a targeted solution designed to complement individuals ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Within one year, 46.5% of patients with type 2 diabetes and 64.8% without type 2 diabetes discontinued GLP-1 RA therapy. Within two years, discontinuation rates increased to 64.1% and 84.4% ...